Skip to main navigation Skip to search Skip to main content

Noncoding RNAs in heart failure

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Heart failure is a major contributor to the healthcare burden and mortality worldwide. Current treatment strategies are able to slow down the transition of healthy heart into the failing one; nevertheless better understanding of the complex genetic regulation of maladaptive remodeling in the failing heart is essential for new drug discovery. Noncoding RNAs are key epigenetic regulators of cardiac gene expression and thus significantly influence cardiac homeostasis and functions. In this chapter we will discuss characteristics of noncoding RNAs, especially miRNAs, long noncoding RNAs, and circular RNAs, and review recent evidences proving their profound involvement during different stages of heart failure progression. Several open questions still prevent the extensive use of noncoding RNA-modulating therapies in clinics; yet they are becoming an attractive target to define novel regulatory mechanisms in the heart. In-depth study of their interaction with gene networks will refine our current view of heart failure and revolutionize the drug development in coming years.

Original languageEnglish (US)
Title of host publicationHandbook of Experimental Pharmacology
PublisherSpringer New York LLC
Pages423-445
Number of pages23
DOIs
StatePublished - 2017
Externally publishedYes

Publication series

NameHandbook of Experimental Pharmacology
Volume243
ISSN (Print)0171-2004
ISSN (Electronic)1865-0325

Keywords

  • Circular RNA
  • Heart failure
  • Long noncoding RNAs
  • miRNAs
  • ncRNA therapy

ASJC Scopus subject areas

  • Biochemistry
  • General Pharmacology, Toxicology and Pharmaceutics

Fingerprint

Dive into the research topics of 'Noncoding RNAs in heart failure'. Together they form a unique fingerprint.

Cite this